Substitute t	for form 1449A/PTO			Co	omplete if Known	0
				Application Number		Q _
INFORMATION DISCLOSURE				Filing Date		- 6
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	David WALLACH	ω <u>6</u>
				Group Art Unit	1644	-0
(use as many sheets as necessary)			ecessary)	Examiner Name		10
Sheet	1	of	4	Attorney Docket Number	WALLACH=10D	- OF 1

U.S. PATENT DOCUMENTS							
Cite No. <sup>1</sup>	U.S. Patent Number	Document Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
AA	4,677,063		Mark et al	06-30-1987			
AB	4,898,818		Nakai et al	02-06-1990			
AC	4,948,875		Tanaka et al	08-14-1990			
AD	4,990,455		Yamagishi et al	02-05-1991			
AE	5,344,915		LeMaire	09-06-1994			
AF	6,232,446	B1	Wallach et al	05-15-2001			
- "·							
	<u>-</u>						
	<u>.</u>						
				-			
			74 . · · · · · · · · · · · · · · · · · ·				
				<del>-</del>			
	- ;						
		7					
	AA AB AC AD AE	Cite Number  AA 4,677,063  AB 4,898,818  AC 4,948,875  AD 4,990,455  AE 5,344,915	No.1 Number (if known)  AA 4,677,063  AB 4,898,818  AC 4,948,875  AD 4,990,455  AE 5,344,915	U.S. Patent Document           No.1         Number         Kind Code (if known)         Name of Patentee or Applicant of Cited Document           AA         4,677,063         Mark et al           AB         4,898,818         Nakai et al           AC         4,948,875         Tanaka et al           AD         4,990,455         Yamagishi et al           AE         5,344,915         LeMaire	Cite No.1         Number         Kind Code² (if known)         Name of Patentee or Applicant of Cited Document         Date of Publication of Cited Document MM-DD-YYYY           AA         4,677,063         Mark et al         06-30-1987           AB         4,898,818         Nakai et al         02-06-1990           AC         4,948,875         Tanaka et al         08-14-1990           AD         4,990,455         Yamagishi et al         02-05-1991           AE         5,344,915         LeMaire         09-06-1994		

				FOREIG	N PATENT DOCUMEN	TS		
			Foreign Patent Nu	mber	Name of Detentes on Annihous	Date of Publication	Pages, Columns, Lines,	
Examiner Initials*	Cite No. <sup>1</sup>	Office <sup>3</sup>	Number	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	AG	EP	0 334 185	A2	Wendt	09-27-1989		
	АН	EP	0 398 327	B1	Engelmann et al	11-22-1990		
	Al	AU	58976/90		Thompson et al	01-24-1991		
	AJ	EP	0 418 014	B1	Beckmann et al	03-20-1991		
	AK	EP	0 648 783	B1	Mett et al	04-19-1995		
			<del></del>					
			<del></del>					

Examiner	Date	
Signature	Considered	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449A/PTO			Complet if Known				
				Application Number				
INFO	RMATION	DISC	LOSURE	Filing Date				
STAT	EMENT BY	/ AP	PLICANT	First Named Inventor	David WALLACH			
<b>O</b> 17(1		. ,		Group Art Unit	1644			
	(use as many she	ets as n	ecessary)	Examiner Name		·		
Sheet	2	of	4	Attorney Docket Number	WALLACH=10C			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AL	BALAVOINE et al, "Prostaglandin E <sub>2</sub> and Collagenase Production by Fibroblasts and Synovial Cells Is Regulated by Urine-Derived Human Interleukin 1 and Inhibitor(s)", <u>J Clin Invest</u> 78:1120-1124 (1986)	
	AM	BEUTLER et al, "Passive Immunization against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin", Science 229:869-871 (1985)	
	AN	BEUTLER et al, "Cachectin: More than a Tumor Necrosis Factor", New Eng J Med 316(7):379-385 (1987)	
	AO	BEUTLER et al, Tumor Necrosis Factors, Raven Press, New York, pp. 145, 383 (1992)	
	AP	BIGDA et al, "Dual Role of the p75 Tumor Necrosis Factor (TNF) Receptor in TNF Cytotoxicity", <u>J Exp Med</u> 180:445-460 (1994)	
	AQ	BROCKHAUS et al, "Monoclonal Antibodies against the TNF-Receptor Inhibit", 2 <sup>nd</sup> Int'l Conf. Tumor Necrosis Factor and Related Cytokines, Jan 15-20, 1989, p. 140	
	AR	BROCKHAUS et al, "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies", Proc Natl Acad Sci U S A 87(8):3127-3131 (1990)	
	AS	CHEN et al, "Mapping the domain(s) critical for the binding of human tumor necrosis factor-alpha to its two receptors", <u>J Biol Chem</u> 270(6):2874-2878 (1995) (Abstract)	
	AT	CREASEY et al, "Biological Effects of Recombinant Human Tumor Necrosis Factor and Its Novel Muteins on Tumor and Normal Cell Lines", Cancer Research 47:145-149 (1987)	
	AU	ENGELMANN et al, "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine", <u>J Biol Chem</u> 265(3):1531-1536 91990)	_
	AV	HARRIS et al, "Therapeutic antibodies - the coming of age", TIBTECH 11:42-44 (1993)	
·	AW	HIGUCHI et al, "Modulation of two forms of tumor necrosis factor receptors and their cellular response by soluble receptors and their monoclonal antibodies", <u>J Biol Chem</u> 267(29):20892-20899 (1992)	

Examiner	Date	
Signature	Considered	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO	Complete if Known				
	Application Number				
INFORMATION DISCLOSURE	Filing Date				
STATEMENT BY APPLICANT	First Named Inventor	David WALLACH			
	Group Art Unit	1644			
(use as many sheets as necessary)	Examiner Name				
Sheet 3 of 4	Attorney Docket Number	WALLACH=10C			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	AX	HOHMANN et al, "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)", J Biol Chem 264(25)14927-14934 (1989)	
	AY	HOHMANN et al, "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)", 2 <sup>nd</sup> Int'l Conf. Tumor Necrosis Factor and Related Cytokines, Jan 15-20, 1989, p. 143	_
	AZ	LOETSCHER et al, "Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells", <u>J Biol Chem</u> .265(33):20131-20138 (1990)	
	ВА	NATANSON et al, "Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis", Annals of Int Med 120(9):771-783 (1994)	
	ВВ	PARRILLO JE, "Pathogenetic Mechanisms of Septic Shock", New Eng J Med 328(20):1471-1477 (1993)	
	ВС	PEETRE et al, "A tumor necrosis factor binding protein is present in human biological fluids", Eur J Haematol 41:414-419 (1988)	
į	BD	SCHALL et al, "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor", Cell 61:361-370 (1990)	
	BE	SECKINGER et al, "A Human Inhibitor of Tumor Necrosis Factor alpha", <u>J Exp Med</u> 167:1511-1516 (1988)	
	BF	SMITH et al, "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins", Science 248:1019-1023 (1990)	
	BG	STAUBER et al, "Human Tumor Necrosis Factor-alpha Receptor", <u>J Biol Chem</u> 263(35):19098-19104 (1986)	
	BH	TRACEY et al, "Shock and Tissue Injury Induced by Recombinant Human Cachectin", Science 234:470-474 (1986)	
		TRACEY et al, "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia"  Nature 330:662-664 (1987)	

Signature Considered ·	Examiner	Date	
	Signature	Considered	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute t	for form 1449A/PTO			Complete if Kn wn				
				Application Number				
INFO	RMATION D	ISC	LOSURE	Filing Date				
STAT	EMENT BY	ΔP	PLICANT	First Named Inventor	David WALLACH			
• 17 (1				Group Art Unit	1644			
	(use as many sheets	s as n	ecessary)	Examiner Name				
Sheet	4	of	4	Attorney Docket Number	WALLACH=10C			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	BJ	UNGLAUB et al, "Downregulation of Tumor Necrosis Factor (TNF) Sensitivity Via Modulation of TNF Binding Capacity by Protein Kinase C Activators", <u>J Exp Med</u> 166:1788-1797 (1987)	
	ВК	WALLACH D, "Cytotoxins (Tumor Necrosis Factor, Lymphotoxin and Others); Molecular Functional Characteristics and interactions with interferons", Interferon 7:90-124 (1986)	
	BL	WEIR (Ed.), Handbook of Experimental Immunology, Vol. 1, Blackwell Scientific Publications; Oxford, pp. 8.14-8.15	
	ВМ	WHITLOW et al, "Single-Chain Fv Proteins and Their Fusion Proteins", Methods 2(2):97-105 (1991)	
Examir	her	Date	

Signature Considered

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.